Document is current
Any future updates will be listed below
-
Authors
Ha, Woo-Seok
Chu, Min Kyung
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (NRF) grant from the Korean government (2022R1A2C1091767)
The Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HV22C0106)
- License Information
-
More Information
Article History
Received: 30 January 2024
Accepted: 30 May 2024
First Online: 7 June 2024
Declarations
:
: Not applicable.
: Not applicable.
: MKC was the site investigator for a multicenter trial sponsored by Biohaven Pharmaceuticals, Allergan Korea, and the Ildong Pharmaceutical Company. He has received lecture honoraria from Eli Lilly and Company, Handok-Teva, and the Ildong Pharmaceutical Company over the past 24 months. He received grants from the Yonsei University College of Medicine (6-2021-0229), the Korea Health Industry Development Institute (KHIDI) (HV22C0106), and an NRF grant from the Korean government (MSIT) (2022R1A2C1091767). The authors have no conflicts of interest to declare.
